

Haematologica  
HAEMATOL/2019/235721  
Version 3

Measurable residual disease monitoring provides insufficient lead-time to prevent morphologic relapse in the majority of patients with core-binding factor acute myeloid leukemia

Robert Puckrin, Eshetu G. Atenafu, Jaime O. Claudio, Steven Chan, Vikas Gupta, Dawn Maze, Caroline McNamara, Tracy Murphy, Andre C. Shuh, Karen Yee, Hassan Sibai, Mark D. Minden, Cuihong Wei, Tracy Stockley, Suzanne Kamel-Reid, and Aaron D. Schimmer

Disclosures: ADS has received honorarium from Novartis, Jazz, and Otsuka Pharmaceuticals and research support from Medivir AB and Takeda. A.D.S. is named as an inventor on a patent application related to the use of DNT cells in AML. A.D.S. owns stock in AbbVie Pharmaceuticals. VG received honorarium, research funding through institution, and served on advisory board of Novartis and Incyte. CM has received honorarium from Novartis.

Contributions: RP performed research, performed data analysis, and wrote the manuscript. EA performed data analysis. JO, SC, VG, DM, CM, TM, AS, KY, HS, MM, CW, TS, and SK contributed to performing research and writing the manuscript. AS supervised the study and contributed to writing the manuscript.